| Filed | Form | Description | |
|---|---|---|---|
| 4/24/25 | DEFA14A | DEFA14A | → |
| 4/24/25 | DEF 14A | DEF 14A | → |
| 4/24/24 | DEFA14A | DEFA14A | → |
| 4/24/24 | DEF 14A | DEF 14A | → |
| 4/27/23 | DEFA14A | DEFA14A | → |
| 4/27/23 | DEF 14A | DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 3/9/26 | 4 | 4 | → |
| 3/9/26 | 4 | 4 | → |
| 3/9/26 | 4 | 4 | → |
| 3/9/26 | 4 | 4 | → |
| 3/9/26 | 4 | 4 | → |
| 3/4/26 | 4 | 4 | → |
| ↓ | |||
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.